Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: smallbowelcellcarcinomadisease
  Phrases that lowered it: patients whodays beforeglioblastomatrial iscriteria patients
• Sponsor's past termination rate: 2.7% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 284 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 224 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 72.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery NCT00891072 · started 2009 · scored riskier than 50% of active trials completed
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer NCT03107780 · started 2018 · scored riskier than 97% of active trials terminated
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 NCT03332355 · started 2017 · scored riskier than 34% of active trials terminated
• Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy NCT02047214 · started 2014 · scored riskier than 82% of active trials terminated
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma NCT01849146 · started 2013 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.